• Atossa Therapeutics on May 20, 2026 announced acceptance of a review manuscript outlining how (Z)-endoxifen could modulate utrophin pathways as a potential treatment approach for Duchenne muscular dystrophy.
• No clinical study results were presented; the publication frames a mechanistic rationale and sets up future preclinical evaluation, with biomarker work intended to support later development decisions.
• The article argues (Z)-endoxifen may help create conditions that support utrophin-driven muscle stabilization and repair, potentially affecting key disease processes such as inflammation and fibrosis.
• The work builds on a 2025 Atossa-authored paper that proposed a broader therapeutic rationale for (Z)-endoxifen in Duchenne muscular dystrophy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605201645PR_NEWS_USPR_____SF64543) on May 20, 2026, and is solely responsible for the information contained therein.